Previous 10 | Next 10 |
ZUG, Switzerland, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, will attend the 2023 Cantor Global Healthcare Conference, taking place in...
ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for ePoster presentation ...
ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, will attend the Morgan Stanley 21st Annual Global Healthcare Conference, ...
ZUG, Switzerland, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of three abstracts for presentation at the ...
2023-08-15 12:49:49 ET More on Pharvaris Pharvaris: FDA Lifts Clinical Hold, Progresses HAE Drug Development Pharvaris stock climbs 13% after FDA lifts hold on HAE drug candidate Pharvaris adds 58% on positive data from mid-stage hereditary angioedema trial P...
2023-08-15 10:17:36 ET Gainers: Delcath Systems ( DCTH ) +90% . Pharvaris ( PHVS ) +22% . ENDRA Life Sciences ( NDRA ) +14% . NeurAxis ( NRXS ) +12% . SomaLogic ( SLGC ) +12% . Losers: Design Therapeutics ( DSGN ) -6...
2023-08-07 09:29:42 ET Pharvaris press release ( NASDAQ: PHVS ): Q2 GAAP EPS of -$0.63. Cash and cash equivalents were €179 million as of June 30, 2023, compared to €162 million for December 31, 2022. Research and Development (R&D) Expenses. R&D e...
Enrollment completed in Phase 2 CHAPTER-1 prophylactic study; top-line data anticipated by YE2023 Clinical hold lifted on deucrictibant for the on-demand treatment of HAE; initiation of global Phase 3 clinical study (RAPIDe-3) anticipated by YE2023 Completed $70 million private placement;...
2023-07-27 03:31:48 ET Summary Pharvaris, a clinical-stage company, has reported a cash position of €135 million as of March 31, 2023, indicating an operational runway of approximately 18 months at current loss rates. The company's product pipeline, including PHVS416 and PH...
ZUG, Switzerland, July 21, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today shared data from the RAPIDe-1 Phase 2 clinical study of PHVS416 (deu...
News, Short Squeeze, Breakout and More Instantly...
Pharvaris N.V. Company Name:
PHVS Stock Symbol:
NASDAQ Market:
2024-06-13 23:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Deucrictibant substantially resolved symptoms of an HAE attack in 78.6% participants within 24 hours High treatment satisfaction of deucrictibant driven by favorable effectiveness subdomain score compared to placebo ZUG, Switzerland, June 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasd...
2024-06-02 07:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...